drugset / Trial / NCT06125106

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

NCT06125106

Phase 1 Unknown 31 enrolled Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab

Timeline

Start
2023-11-16
Primary completion
2025-01-01
Completion
2026-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Blinatumomab Monoclonal antibody 28 ug Intravenous